LifeArc makes $30M Kymab investment to access antibody tech
Kymab is set to receive a $30 million investment from LifeArc in return for access to antibody discovery technologies.
Kymab is set to receive a $30 million investment from LifeArc in return for access to antibody discovery technologies.